Hologic — Cytyc — Merger or Acquisition (June 2007)
13 slides from Hologic's merger presentation, Jun 13, 2007
Slide 1: Creating a Global Leader in Women’s Healthcare
Filed by Hologic, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company:Cytyc Corporation Commission File No.: 000-27558 Creating a Global Leader in Women’s Healthcare Continuing a legacy of leading
Slide 2: Disclaimer Regarding Forward-Looking Statements
Disclaimer Regarding Forward-Looking Statements Forward-Looking Statements Regarding Cytyc Investors are cautioned that statements in this presentation which are not strictly historical statements, including, without limitation, Cytyc's future financial condition, operating results and economic perf
Slide 3: Disclaimer Regarding Forward-Looking Statements (continued)
Disclaimer Regarding Forward-Looking Statements (continued) financial statements for the period 1996 through 2002, relating to certain employee stock option exercises, including the impact of the expected any regulatory review or litigation relating to such matters, the impact of new accounting requ
Slide 4: Disclaimer Regarding Forward-Looking Statements (continued)
Disclaimer Regarding Forward-Looking Statements (continued) Forward-Looking Statements Regarding the Proposed Hologic-Cytyc Transaction This presentation also includes forward-looking statements about the timing of the completion of the transaction, the anticipated benefits of the business combinati
Slide 5: Disclaimer Regarding Forward-Looking Statements (continued)
Disclaimer Regarding Forward-Looking Statements (continued) significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies, including third-p
Slide 6: Important Information for Investors and Stockholders
Important Information for Investors and Stockholders Hologic and Cytyc will file a joint proxy statement/prospectus with the SEC in connection with the proposed merger. HOLOGIC AND CYTYC URGE INVESTORS AND STOCKHOLDERS TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OT
Slide 7: Participants in the Solicitation
Participants in the Solicitation Hologic, and certain of its directors and executive officers, may be deemed participants in the solicitation of proxies from the stockholders of Hologic in connection with the merger. The names of Hologic’s directors and executive officers and a description of their
Slide 8: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures "adjusted EPS" and “EBITDA”. Adjusted EPS excludes the write-off and amortization of acquisition-related intang
Slide 9: A History of Innovation
Announced A History of Innovation Introduced Agreement with Tomosynthesis at Cytyc RSNA Launched $720E Acquisition Discovery of Direct $463M Radiography $288M 2007 2006 Fan-Beam 2005 Technology 2004 2003 2002 2000 Founding of 1999 Introduced HOLOGIC 3D DEXA 1998 1995 Selenia 1990 Launched 1986 in U.
Slide 10: Creating a Global Leader in Women’s Healthcare
Creating a Global Leader in Women’s Healthcare Strategic Advantages Combined Strengths Expanded Product Portfolio Market Share Leader in Major Product Lines Ability to Leverage OB/GYN Channel Comprehensive Sales Coverage Ability to leverage Surgical and Radiation Oncology channel for Hologic’s new P
Slide 11: Comprehensive Women’s Healthcare Platform
Comprehensive Women’s Healthcare Platform ThinPrep Pap Test & Imaging System FullTerm - Adeza Cervical Cancer Screening Preterm Labor Selenia NovaSure Breast Cancer Best-in-Class Solutions Endometrial Screening Ablation for Women’s Healthcare Adiana Contraception MultiCare Stereotactic Discovery Bio
Slide 12: Diversified and Balanced Revenue Mix
Diversified and Balanced Revenue Mix Hologic Other 12% Combined Company Breast Biopsy 9% Digital Osteoporosis Mammography & Other Osteoporosis 68% 11% 11% Gynecology Interventional Breast Health LQA Revenue = $724M 16% 40% Other Cytyc 1% MammoSite Gynecology 5% Diagnostics 33% Adeza 8% NovaSure Pap
Slide 13: Long-Term Strategic Goals
Long-Term Strategic Goals Drive market growth through a combination of advanced technology and comprehensive sales channel coverage #1 market position in major areas of women’s healthcare Continue 20%+ revenue and earnings growth Develop additional best-in-class products that provide earlier and bet